5 Successful Phase III Oncology Trials in Q1

In the oncology space, drug developers are keen to develop cutting-edge solutions—and lay claim to a piece of a market estimated to hit $359.1 billion by 2028. However, most Phase III trials fail to present significant clinical improvements on the standard of care.

"Oncology . . . is huge because there are some successes, but there’s still a huge medical need,” Ansbert Gadicke, managing partner at MPM BioImpact, told BioSpace earlier this year.